SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.

* Patients with pathologically confirmed selected tumor types (at site or centrally); * Mandatory availability of adequate human biological material (HBM); * Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements; * Age ≥ 12 years; * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; * Written informed consent according to applicable legal and ethical requirements;